scholarly journals Prevalence of low bone mineral density among HIV patients on long-term suppressive antiretroviral therapy in resource limited setting of western India

2014 ◽  
Vol 17 ◽  
pp. 19567 ◽  
Author(s):  
Ameet Dravid ◽  
Milind Kulkarni ◽  
Amit Borkar ◽  
Sachin Dhande
Keyword(s):  
Bone Mineral Density ◽  
Antiretroviral Therapy ◽  
Bone Mineral ◽  
Resource Limited Setting ◽  
Western India ◽  
Mineral Density ◽  
Hiv Patients ◽  
Resource Limited ◽  
Limited Setting

scholarly journals Bone Mineral Density Increases in HIV-Infected Children Treated With Long-term Combination Antiretroviral Therapy

2012 ◽  
Vol 56 (4) ◽  
pp. 583-586 ◽  
Author(s):  
Madeleine J. Bunders ◽  
Olivier Frinking ◽  
Henriette J. Scherpbier ◽  
Lotus A. van Arnhem ◽  
Berthe L. van Eck-Smit ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Antiretroviral Therapy ◽  
Bone Mineral ◽  
Combination Antiretroviral Therapy ◽  
Mineral Density

Association Between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-Term TDF-Based Antiretroviral Therapy

2020 ◽  
Vol 18 ◽  
Author(s):  
Zhijie Xu ◽  
Pengyuan He ◽  
Jianzhong Xian ◽  
Wuzhu Lu ◽  
Jingxian Shu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Liver Disease ◽  
Antiretroviral Therapy ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Bone Mineral ◽  
Fatty Liver Disease ◽  
Mineral Density ◽  
Nonalcoholic Fatty Liver

Background: Tenofovir (TDF) has a detrimental effect on bone mineral density (BMD), while nonalcoholic fatty liver disease (NAFLD) is associated with a lower BMD. Objective: To help understand the mutual effects of NAFLD and TDF on BMD, this study was designed to explore the potential association between NAFLD and BMD in HIV-infected patients receiving long-term TDF-based antiretroviral therapy (ART). Method: A total of 89 HIV-infected patients who received TDF-based ART for more than three years were enrolled in this cross-sectional study. We measured BMD using an ultrasonic bone density apparatus, and liver ultrasonography was performed to determine the severity of the fatty liver. The association of NAFLD with BMD was examined using multiple logistic regression analyses. Results: Patients with NAFLD showed a worse BMD status than those without NAFLD. The incidences rates of osteopenia (42.86% versus 25.93%) and osteoporosis (17.14% versus 3.70%) were significantly higher in HIV-infected patients with NAFLD than in those without NAFLD. After multivariate adjustment, the odds ratio (OR) for patients with NAFLD exhibiting a worse BMD status compared with those without NAFLD was 4.49 (95% confidence interval [CI] 1.42, 14.15). Conclusion: Based on our results, NAFLD was significantly associated with a worse BMD status, including osteopenia and osteoporosis, in HIV patients after receiving long-term TDF-based ART. Furthermore, we may want to avoid using TDF for ART in HIV-infected patients with NAFLD.

Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

2020 ◽  
Vol 36 (5) ◽  
pp. 399-405
Author(s):  
Camille Couffignal ◽  
Sami Kolta ◽  
Martin Flamant ◽  
Charles Cazanave ◽  
Jean-Philippe Haymann ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Antiretroviral Therapy ◽  
Bone Mineral ◽  
Mineral Density ◽  
Hiv 1

Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy

2019 ◽  
Vol 105 (4) ◽  
pp. 423-429
Author(s):  
Mark J. Bolland ◽  
Anne M. Horne ◽  
Simon E. Briggs ◽  
Mark G. Thomas ◽  
Ian R. Reid ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bone Mineral Density ◽  
Antiretroviral Therapy ◽  
Bone Mineral ◽  
Mineral Density

scholarly journals Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246389
Author(s):  
Erisa Sabakaki Mwaka ◽  
Ian Guyton Munabi ◽  
Barbara Castelnuovo ◽  
Arvind Kaimal ◽  
William Kasozi ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Antiretroviral Therapy ◽  
Bone Mass ◽  
Bone Mineral ◽  
People Living With Hiv ◽  
Low Bone Mass ◽  
Mineral Density ◽  
Living With Hiv

Background This study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV. Methods A cross-sectional study was conducted among 199 people living with HIV that had been on anti-retroviral therapy for at least 10 years. All participants had dual X-ray absorptiometry to determine their bone mineral density. The data collected included antiretroviral drug history and behavioral risk data Descriptive statistics were used to summarize the data. Inferential statistics were analyzed using multilevel binomial longitudinal Markov chain Monte Carlo mixed multivariate regression modelling using the rstanarm package. Results One hundred ninety nine adults were enrolled with equal representation of males and females. The mean age was 39.5 (SD 8.5) years. Mean durations on anti-retroviral treatment was 12.1 (SD 1.44) years, CD4 cell count was 563.9 cells/mm3. 178 (89.5%) had viral suppression with <50 viral copies/ml. There were 4 (2.0%) and 36 (18%) participants with low bone mass of the hip and lumbar spine respectively. Each unit increase in body mass index was associated with a significant reduction in the odds for low bone mineral density of the hip and lumbar spine. The duration on and exposure to the various antiretroviral medications had no significant effect on the participant’s odds for developing low bone mass. All the coefficients of the variables in a multivariable model for either hip or lumbar spine bone mass were not significant. Conclusion These results provide additional evidence that patients on long term ART achieve bone mass stabilization. Maintaining adequate body weight is important in maintaining good bone health in people on antiretroviral therapy.

Sign in / Sign up

Export Citation Format

Share Document